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Purpose: Overweight individuals are at risk of intermediate hyperglycemia 
(IHG) [1]. Increasing physical activity (PA) in IHG is one method to reduce 
the risk of glucometabolic and cardiovascular (CV) complications [2]. This 
study investigates walking to music as a modality to increase moderate inten-
sity PA and regulate glucometabolic disturbances. Patients and Methods: 
Participants were randomized to usual care (UC) or intervention group (IG) 
who completed a 6 month walking to music program. Physiological assess-
ments for a range of variables (DEXA, flow mediated dilatation (FMD) and 
glucometabolic biomarkers) were completed at baseline, 4, 6 and 9 months 
(follow-up). Results: For IG group, walking compliance decreased with time 
however 71.4%, 79.5% and 73% of walking completed was moderate intensity 
at 4, 6 and 9 months. At 6 months IG FMD was significantly lower than UC 
and HbA1Cwas 5% lower. Other physiological markers were not altered. Con- 
clusion: Walking to music may be a novel method to encourage moderate 
intensity PA. However, the majority of results demonstrate that this inter- 
vention was not more effective than UC in managing glucometabolic and CV 
biomarkers in IHG. Future interventions should include additional support 
for the entire study duration however this has cost implications. 
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1. Introduction 
Excess adiposity continues to present significant health and social problems [3]. 
Adults carrying excess adipose tissue are at higher risk of developing co-morbi- 
dities such as impaired glucose metabolism and cardiovascular disease (CVD) 
and have increased mortality rates [4]. As adiposity increases beyond a body 
mass index (BMI) of 25 kg/m2, the risk of the development of type 2 diabetes 
mellitus (T2DM) also increases [5]. Many adults with hyperglycemia remain in 
an asymptomatic state for a prolonged period before T2DM diagnosis [6]. This 
intermediate hyperglycemia (IHG) includes impaired glucose tolerance (IGT) 
and/or impaired fasting glucose [1]. In addition to the impaired handling of glu-
cose, IHG can increase oxidative stress, inflammation and endothelium dysfunc-
tion [6] [7] [8]. Approximately 86 million (37% of the adult US population) meet 
the diagnostic criteria for IHG [9]. In the UK, around 7 million people are thought 
to have IHG [2] with estimates suggesting that 1 in 3 English adults have IHG 
[2] [10]. Like the majority of the population, less than half of this population 
report completing current PA guidelines [11]. It is well established that increas-
ing PA in IHG is one method to reduce the risk of glucometabolic and CVD 
complications [2]. Moderate intensity exercise in particular is required to regu-
late hyperglycaemia by increasing GLUT-4 translocation to muscle tissue, en-
hancing uptake of glucose via PI-3K and MAP kinase pathways [12]. Similar ef-
fects are noted for the reduction of inflammation associated with diabetic pro-
gression [13]. Recent studies have calculated that £1 million per hour is spent 
from the National Health Service (NHS) budget on diabetes health care costs [14]. 
As such, preventing progression from IHG to T2DM using low cost, effective 
and sustainable methods is important for public health. Assisting individuals to 
achieve and maintain moderate intensity exercise remains problematic. Previous 
research has used heart rate monitors, self-report methods and accelerometers/ 
pedometers as tools, but many of these possess limitations from a user’s perspec-
tive, but also a research reliability and validity perspective [15]. Using music 
with a pre-determined tempo to help stimulate and regulate cyclic PA intensity 
may ensure PA is regularly performed at the desired intensity [16].  
The aims of this study were to examine the effects of a walking to music in-
tervention to encourage a pace which achieves moderate intensity on glycemic 
control, oxidative stress, endothelial dysfunction and inflammatory markers in 
IHG.  
2. Methodology  
Following approval by Ulster University Research Ethics Committee and the Of-
fice for Research Ethics Northern Ireland (Approval number: 12/NI/0063), over-
weight and obese IHG adults who met the diagnostic criteria of a fasting plasma 
glucose between 5.6 - 6.9 mmol/L−1 or a two hour glucose concentration be-
tween 7.8 - 11.0 mmol/L−1 (n = 42), were recruited from consultant led diabetic 
clinics and from a university within Northern Ireland (Figure 1). Exclusion  
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Figure 1. Flowchart of IG and UC participants from baseline to 9 months. 
 
criteria for the study included those who had progressed to T2DM/those who 
had normoglycaemia, those under the age of 18 or over the age of 65. Partici-
pants were also excluded if they were smokers, had a history of cardiovascular 
events, or were taking any medication which would interfere with the blood 
biomarkers assessed. Participants provided medical history details and informed 
consent before random assignment to an intervention group (IG) (n = 22) or 
usual care group (UC) (n = 20) (Figure 1). IG participants (n = 17) received an 
individualized 6 month walking program designed to increase moderate intensi-
ty walking to 30 minutes per day based on current PA guidelines [17]. Self-chosen 
music with a predetermined tempo was selected based upon height-related stride 
rate recommendations by Rowe et al. [18] to elicit moderate intensity exercise 
for each individual (50% - 70% maximum HR, 90 - 113 steps/min). Cadence 
(steps/min−1) was recorded using the inbuilt MP3 accelerometer and analyzed 
via MATLAB (MATLAB, The Mathworks Inc, Natick, MA, 2014). IG received 
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three physical activity consultations (PACS) during the 9 month intervention (0, 
4 and 6 months) based on the work of Kirk and colleagues [19]. These were 
complimented by booster telephone sessions to revise goals, barriers to exercise 
and methods of achieving PA targets. UC participants (n = 20) received an in-
formation sheet detailing current PA guidelines and methods to achieve these on 
a weekly basis (this is the usual care those with IHG currently receive from the 
NHS). All measurements were completed at baseline, 4, 6 and 9 months (Figure 
1).  
2.1. Physiological Testing  
Height (cm) and body mass (kg) were recorded and BMI (kg/m2) calculated 
[20]. Arterial blood pressure was measured in a supine position (Omron M5-1 
BP monitor, Surrey, UK). DXA was used to measure whole and regional body 
composition and bone. Arterial stiffn-ness was assessed using a PulseTrace Pulse 
Contour Analysis (PCA) system (Micro Medical, UK). A 2D high resolution 
Sonoace Pico ultrasound system (GE Healthcare, Memphis TN) was used to as-
sess endothelial function according to the methods of Harris et al. [21]. Physical 
fitness was measured via a sub-maximal graded exercise assessment using walk-
ing speeds determined by the ACSM metabolic equations [22]. Stages were 4 
minutes in duration and consisted of three stages (12 minutes in total). Heart 
rate response and respiratory exchange values at each workload (km/hr−1) meas-
ured walking economy. PA was assessed via a self-administered International 
Physical Activity Questionnaire (IPAQ) short version [23]. IG intervention % 
walking compliance was assessed by comparing the app-recorded walks (for vo-
lume and duration) to walking prescribed in each program. Intensity compliance 
(%) was assessed by calculating the number of walks that, on average, were at/ 
above the predetermined target cadence. Both groups recorded PA in a logbook 
at each timepoint. At each timepoint, all participants completed a cadence walk 
around an elliptical track (≥eight minutes) to ensure that the desired stride rate 
and moderate intensity exercise was completed. Fasted blood samples were as-
sessed for the following metabolites. Glucometabolic status: fasting plasma glu-
cose, oral glucose tolerance test (OGTT [24]), glycosylated hemoglobin (HbA1C) 
and insulin; Lipoproteins: serum total cholesterol, high-density lipoprotein cho-
lesterol (HDL-C), calculated low-density lipoprotein cholesterol (LDL-C) (Fried 
Wald et al. [25]) and serum triglyceride (TRIG). Inflammatory markers: tumor 
necrosis factor-α (TNF-α), interleukin 6 (Il-6) and high-sensitivity C reactive 
protein (Hs-CRP); Oxidative stress markers: Lipid hydroperoxides (LOOHs) 
(FOX assay), lipid soluble antioxidants (γ-tocopherol, α-tocopherol; Retinol; Ly-
copene; β-carotene, α-carotene) and ascorbyl free radical. Hematocrit and he-
moglobin were also assessed via standard methods.  
2.2. Data Analysis  
Levene’s test for equality of variances (p > 0.05) were performed to investigate 
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homogeneity of variance. Independent-sample t-tests (P) (p < 0.05) were used to 
compare themeans of two groups’ (IG vs. UC). A repeated measures GLM was 
utilized to assess the difference between variables with one between-subjects va-
riable (two groups IG and UC), one within subject variable with two or more le-
vels (e.g.4 time points: baseline, 4, 6 and 9 months) and one continuous depen-
dent variable (parameter measurement) (p < 0.05). All data is presented as mean 
value ± standard deviation (SD) unless otherwise stated. Descriptive statistics 
(means or frequencies) were calculated where appropriate. All statistical analysis 
was completed using Microsoft Excel and SPSS version 22.0, for windows (SPSS, 
Chicago, IL). 
3. Results  
3.1. Vascular Function and CVD Risk  
No statistically significant interaction (time × group) effects, main (time) effects 
or main (group) effects (p > 0.05) were observed for systolic and diastolic blood 
pressure (mmHg) or resting heart rate (RHR; BPM−1) across assessment points 
(Table 1). No significant interaction (time × group) effect (m/sec−1) and no sig-
nificant main (group) effect were found for SI (m/sec−1). SI (m/sec−1) displayed a 
significant main (time) effect [F(3, 32) = 2.938, p = 0.048, multivariate partial eta 
squared = 0.216]. Post hoc comparisons found a statistical significance between 
SI baseline and 9-month values (p = 0.03). RI (%) values displayed no significant 
interaction for time × group, time or group effect for RI(%) values. FMD(%) 
displayed a significant interaction effect (time × group) [F(3, 32) = 3.992, p = 
0.016, multivariate partial eta squared = 0.272]. Post hoc analysis found a signif-
icant difference between IG and UC at 6 months (t(34) = 2.74, p = 0.10; 6.51% ± 
4.38% and 11.21% ± 5.72% respectively). A significant increase was observed  
 
Table 1. Summary of vascular function parameters. 
Parameter 
IG participants (n = 17) UC participants (n = 19) 
Baseline 4 months 6 months 9 months Baseline 4 months 6 months 9 months 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Blood pressure 
Systolic (mmHg) 134.12 18.80 133.30 18.71 135.86 16.47 136.74 17.59 138.00 12.06 137.76 16.50 138.52 16.14 136.58 16.63 
Diastolic 
(mmHg) 
81.20 11.81 78.86 9.82 82.73 13.57 81.62 10.55 79.60 8.60 78.21 7.32 77.56 10.59 78.50 9.30 
RHR (bpm) 66.90 10.26 64.49 9.39 66.23 13.93 64.73 10.16 67.96 8.61 69.20 9.43 68.52 8.80 65.60 9.17 
Arterial Stiffness 
SI (m/sec−1) 8.10 1.89 7.45 1.86 7.34 2.03 7.47 1.97 8.07 1.84 7.66 1.73 7.60 1.52 7.13 1.41 
RI (%) 59.59 14.91 60.11 16.1 55.20 14.04 56.16 15.6 50.08 10.63 51.43 12.2 56.89 13.44 57.14 12.34 
FMD (%) 9.50 5.59 7.24 3.15 6.51† 4.38 7.81 3.82 9.66 4.75 7.40^ 2.85 11.21 5.72 8.47 3.81 
RHR = resting heart rate, FMD = flow mediated dilation. A repeated measures GLM (p < 0.05) examined differences between groups across assessment 
points. †Denotes a significant difference between groups (p < 0.05). ^Denotes a within group significant difference between given value and 6 month value (p 
< 0.05).  
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within UC FMD (%) between 4 and 6 months (p = 0.017) with UC FMD per-
centage change increasing by 16.1% between these assessment points (as shown 
in Figure 2). A significant main (time) effect [F(3, 32) = 4.350, p = 0.011, multi-
variate partial eta squared = 0.290] was observed for FMD (%) between baseline 
and 4 months (p = 0.015). No significant main (group) effect was observed.  
3.2. Walking Compliance  
IG % walking compliance from baseline to 4 months was 70.1% ± 39.17% (range 
9.0% to 158.4%). This was followed by decreases to 43.4% ± 56.1% (range 0% to 
225%) between 4 to 6 months and to 37.5% ± 43.5% (range 0% to 125.3%) at 9 
months. Despite this, % intensity compliance of the walks completed was 71.4%, 
79.5% and 73.3% was at least moderate intensity (achieving the predetermined 
target cadence) between baseline to four months, four to six months and six to 
nine months respectively. IPAQ data showed no significant interaction (group × 
time) effect, main (time) effect or main (group) effect in vigorous MET.min/week, 
moderate MET.min/week, walking MET.min/week or total PA MET.min/week 
(p > 0.05). At baseline participants were categorized as low active (50% IG, 35% 
UC), moderately active (30% IG, 50% UC) and highly active (20% IG, 15% UC). 
At 4 months participants were categorized as low active (45% IG, 45% UC), 
moderately active (45% IG, 40% UC) and highly active (10% IG, 15% UC). At 
the end of the intervention (6 months) 55% IG and 50% UC participants were 
categorized as low active, 25% IG and 40% UC were categorized moderately ac-
tive and 20% IG vs. 10% UC were categorized highly active. At follow-up (9 
months) participants were categorized as low active (45% IG, 45% UC), mod-
erately active (50% IG, 45% UC) and highly active (5% IG, 10% UC) (Table 2). 
3.3. Blood Biomarkers  
No significant interaction (time × group) and no main effect for group was  
 
 
Figure 2. FMD (%) across assessment points (IG n = 17, UC n = 19). *A repeated meas-
ures GLM (p < 0.05) examined differences between groups across assessment points. 
†Denotes a significant difference between groups at 6 months (p < 0.05). ^Denotes a 
within group significant difference between given value and 6 month value (p < 0.05) 
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Table 2. IG and UC IPAQ continuous scores. 
IPAQ DATA Assessment 









Baseline 0 480 0 240 
4 months 0 0 0 0 
6 months 0 840 0 0 
9 months 0 0 0 0 
Moderate 
MET.min/week 
Baseline 0 420 360 1248 
4 months 200 400 240 760 
6 months 0 160 0 480 
9 months 0 160 0 520 
Walking 
MET.min/week 
Baseline 247.5 264 594 1204.5 
4 months 396 379.5 462 808.5 
6 months 346.5 660 462 693 




Baseline 396 1811.4 1188 2826.5 
4 months 888 758 933 2535.5 
6 months 792 1653 495 1459.5 
9 months 605.5 1752 990 1683.75 
Continuous IPAQ scores are presented as median and interquartile range. A repeated measures GLM 
found no statistically significant differences between groups across assessment points (p > 0.05). 
 
detected for fasting plasma glucose. Non-significant lowering trends were ob-
served for IG FPG (mmol/L−1) from baseline (6.03 ± 0.36 mmol/L−1) to 4 months 
(5.96 ± 0.49 mmol/L−1) and to 6 months (5.95 ± 0.41 mmol/L−1). IG FPG was 
5.95 ± 0.41 mmol/L−1 at 6 months and 6.04 ± 0.49 mmol/L−1 at 9 months. IG 
FPG at follow-up was lower than that recorded by UC participants (6.04 ± 0.49 
mmol/L−1 vs. 6.10 ± 0.48 mmol/L−1 respectively), this was anon-significant result 
(p > 0.05). No significant interaction (time × group) and no main effect for 
group was detected for two-hour glucose (mmol/L−1). There was a significant 
main (time) effect [F(3, 32) = 3.22, p = 0.036] which displayed a large effect size 
[partial eta squared = 0.23]. Post hoc analysis observed this significant effect for 
two-hour glucose (mmol/L−1) was found between baseline and 6 months (p = 
0.03) and baseline and 9 months (p = 0.03). Although no interaction (group × 
time) effect was found (p > 0.05) the greatest decrease in IG two-hour glucose 
(mmol/L−1) was 13.78% from baseline to 4 months (7.29 ± 2.27 mmol/L−1 to 6.29 
± 1.96 mmol/L−1 respectively). UC two-hour glucose (mmol/L−1) decreased by 
3.77% during the same period (baseline 8.00 ± 2.72 mmol/L−1 to 4 months 7.70 ± 
2.55 mmol/L−1; p > 0.05) (Table 3).  
3.3.1. Glycosylated Hemoglobin (HbA1C; mmol/mol−1) 
No significant interaction (time × group) effect and no significant main (group)  
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Table 3. Blood metabolites. 
Parameter 
IG participants (n = 17) UC participants (n = 19) 
Baseline 4 months 6 months 9 months Baseline 4 months 6 months 9 months 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
FPG (mmol/L−1) 6.03 0.36 5.96 0.49 5.95 0.41 6.04 0.49 6.20 0.47 6.21 0.83 6.18 0.57 6.10 0.48 
2 hr gluc 
(mmol/L−1) 
7.29 2.27 6.29 1.96 6.52 1.68 6.67 1.98 8.00 2.72 7.70 2.55 6.69 2.71 6.35 1.85 
HbA1c 
(mmol/mol−1) 
38.1 5.2 37.7 4.9 36.7 3.9 36.7 4.3 39.4 5.5 37.9 5.8 38.9 5.7 38.5 3.6 
Insulin (pmol/L−1) 105.4 58.27 96.03 31.62 105.6 38.17 112.7 39.40 127.2 98.47 149.7 139.2 121.1 73.47 120.8 62.86 
Haematocrit (%) 41.11 4.28 43.12 3.57 42.72 2.92 43.94 3.97 42.34 3.94 41.69 3.91 43.59 7.15 41.95 5.02 
Haemoglobin 
(g/dL−1) 
13.27 3.04 15.54 2.64 15.29 1.74 15.00 2.15 14.53 1.65 14.91 1.65 15.58 1.51 14.75 2.12 
FPG = fasting plasma glucose, 2 hr gluc = Two-hour glucose, HbA1c = glycated haemoglobin. A repeated measures GLM found no statistically significant 
differences between groups across assessment points (p > 0.05). 
 
effect was detected for HbA1C (mmol/mol−1). There was a significant main (time) 
effect found for HbA1C (mmol/mol−1; Table 3 [F(3, 32) = 3.88, p = 0.01] which 
displayed a large effect size [partial eta squared = 0.267]. The significant main 
(time) effect was observed between baseline and 6 month values HbA1C (p = 
0.01). Although not significant between groups (p > 0.05) at the end of the in-
tervention period (6 months) IG HbA1C was 5.07% lower in comparison to UC 
values (36.76 ± 3.89 mmol/mol−1 and 38.63 ± 5.52 mmol/mol−1 respectively). At 
follow-up (9 months) a 4.00% difference was maintained (IG 36.81 ± 4.29 
mmol/mol−1 vs. UC 38.28 ± 4.37 mmol/mol−1; p > 0.05). 
3.3.2. Insulin 
No significant interaction (time × group) effect with no main (time) effect or no 
significant main (group) effect were found for insulin (p > 0.05; Table 3). No 
significant interaction (time × group) effect with no main (time) effect or no 
main (group) effect (p > 0.05) were found for hematocrit (%) and hemoglobin 
(g/dL−1).  
3.3.3. Lipoproteins (Table 4)  
CHOL (mmol/L−1) results displayed no significant interaction (time × group) 
and no significant main (group) effect. There was a significant main (time) effect 
[F(3, 32) = 5.37, p = 0.00] which displayed a large effect size [partial eta squared = 
0.36] found for CHOL (mmol/L−1). Post hoc comparisons found a significant in-
crease between baseline (4.74 ± 1.02 mmol/L−1) and 6 month (5.06 ± 1.07 
mmol/L−1) CHOL (p = 0.004); (IG baseline and 6 month CHOL was 4.69 ± 1.23 
mmol/L−1 and 4.98 ± 1.17 mmol/L−1 respectively, UC baseline and 6 month CHOL 
was 4.79 ± 0.84 mmol/L−1 5.12 ± 1.01 mmol/L−1 respectively). HDL-C (mmol/L−1) 
displayed no significant interaction (time × group) effect with no main (time) 
effect or no significant main (group) effect (p > 0.05). LDL-C (mmol/L−1) displayed 
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Table 4. Blood metabolites. 
Parameter 
IG participants (n = 17) UC participants (n = 19) 
Baseline 4 months 6 months 9 months Baseline 4 months 6 months 9 months 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Lipoproteins 
CHOL (mmol/L−1) 4.69 1.23 5.04 1.09 4.99 1.17 4.91 0.93 4.79 0.84 4.86 0.76 5.12 1.01 4.85 0.72 
HDL-C (mmol/L−1) 1.02 0.27 1.04 0.21 1.08 0.22 1.13 0.26 1.11 0.31 1.11 0.31 1.15 0.36 1.11 0.24 
LDL-C (mmol/L−1) 1.39 0.57 1.46 0.60 1.47 0.58 1.49 0.66 1.25 0.41 1.38 0.39 1.49 0.49 1.46 0.55 
TRIG (mmol/L−1) 3.05 1.15 3.34 1.01 3.24 1.07 3.11 0.90 3.11 0.77 3.12 0.70 3.30 0.89 3.08 0.78 
Inflammatory markers 
TNF-α (pg/ml−1) 1.35 1.62 9.61 27.60 7.69 19.19 1.09 1.71 0.75 0.68 1.81 4.51 2.00 3.27 0.74 0.63 
IL-6 (pg/ml−1) 29.14 45.29 38.36 47.25 13.82 36.28 33.60 44.16 27.66 38.97 11.57 16.09 14.11 28.52 37.31 36.45 
Hs-CRP (mg/L−1) 3.39 2.65 2.90 2.62 3.03 2.47 2.77 2.22 2.39 1.90 2.45 2.28 2.45 2.28 2.19 1.89 
Oxidative stress markers 
LOOHs (mmol/L−1) 1.46 0.30 1.49 0.21 1.53 0.27 1.63 0.18 1.45 0.16 1.52 0.21 1.57 0.50 1.49 0.26 
γ-tocopherol 
(μmol/L−1) 
2.94¥ 1.21 3.34¥ 1.97 3.31¥ 1.87 5.64 2.39 3.99^ 2.18 3.39 1.99 2.66¥ 0.88 4.30 1.82 
α-tocopherol 
(μmol/L−1) 
25.32¥ 12.59 32.87 15.24 33.14† 15.66 44.50 18.07 34.34 21.39 32.03^ 15.18 21.52¥ 8.59 33.95 14.03 
Retinol (μmol/L−1) 7.95¥ 3.33 9.44 2.56 10.51 6.33 11.41† 4.17 9.70 2.88 9.18 2.83 7.47 2.41 8.92 1.51 
Lycopene (μmol/L−1) 0.26¥ 0.25 0.28¥ 0.13 0.32†¥ 0.16 0.01† 0.04 0.22 0.26 0.33^¥ 0.23 0.21 0.10 0.17 0.12 
β-carotene(μmol/L−1) 0.03 0.03 0.05 0.03 0.04 0.04 0.03 0.03 0.05 0.04 0.07 0.06 0.04 0.03 0.06 0.07 
α-carotene 
(μmol/L−1) 
0.16 0.23 0.17 0.09 0.13 0.10 0.17 0.11 0.24 0.26 0.21 0.20 0.13 0.10 0.23 0.25 
Ascorbyl 4.69 1.23 5.04 1.09 4.99 1.17 4.91 0.93 4.79 0.84 4.86 0.76 5.12 1.01 4.85 0.72 
CHOL = Serum total cholesterol, HDL-C = High-density lipoprotein cholesterol, LDL-C = Low-density lipoprotein cholesterol, TRIG = Serum triglyceride, 
TNF-α = Tumor necrosis factor-α, IL-6 = Interleukin, Hs-CRP = High-sensitivity C-reactive protein, LOOHs = Lipid hydroperoxides, Ascorbyl = Ascorbyl 
free radical. A repeated measures GLM (p < 0.05) examined differences between groups across assessment points. †Denotes a significant difference between 
groups (p < 0.05). ^Denotes a within group significant difference between given value and 6 month value (p < 0.05). ¥Denotes a within group significant 
difference between given value and 9 month value (p < 0.05).  
 
no significant interaction (time × group) effect and no significant main (group) 
effect. There was a significant main (time) effect for LDL-C [F(3, 32) = 5.68, p = 
0.00, multivariate partial eta squared = 0.35]. Post hoc comparisons observed a 
significant increase between LDL-C (mmol/L−1) at baseline and 6 months (p = 
0.02). TRIG (mmol/L−1) displayed no significant interaction (time x group) effect 
and no significant main (group) effect. There was a significant main (time) effect 
[F(3, 32) = 3.56, p = 0.03, multivariate partial eta squared = 0.25]. Post hoc 
comparisons found a significant increase between TRIG (mmol/L−1) at baseline 
and 6 months (p = 0.04). Although no interaction (time × group) effect (p > 
0.05) was observed UC TRIG displayed an increasing trend from baseline to 6 
months by 19.4% in contrast to IG (5.8%). 
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3.3.4. Inflammatory Markers 
TNF-α (pg/ml−1) displayed no significant interaction (time × group) effect and 
no significant main (group) effect. IL-6 (pg/ml−1) displayed no significant inte-
raction (time × group) effect and no significant main (group) effect. There was a 
significant main (time) effect observed [F(3, 32) = 3.56, p = 0.03, multivariate 
partial eta squared = 0.25]. Post hoc comparisons found a significant increase in 
IL-6 (PG/ml−1) between 6 and 9 months (p = 0.03). Hs-CRP (mg/L−1) did not 
display a significant interaction (group × time) effect, with no significant main 
(time) effect and no significant main (group) effect (p > 0.05).  
3.3.5. Oxidative Stress Markers 
No significant interaction (time × group) effect was found for LOOHs (p > 0.05). 
No significant differences were observed for LOOHs (mmol/L−1) for main (time) 
effect and main (group) effect (p > 0.05). Lipid soluble antioxidants (γ-tocopherol, 
α-tocopherol; Retinol, Lycopene, β-carotene, α-carotene γ-tocopherol (μmol/L−1) 
displayed a significant interaction (time × group) effect [F(3, 32) = 3.05, p = 
0.03, multivariate partial eta squared = 0.22]. Post hoc comparisons found sig-
nificant differences existed within groups. Statistical significance was found be-
tween IG baseline and 9 month (p < 0.01), 4 and 9 month (p < 0.01) and between 
6 and 9 month (p = 0.02) γ-tocopherol (μmol/L−1) values. UC γ-tocopherol 
(μmol/L−1) values significantly differed between baseline and 6 months (p < 0.01) 
and between 6 and 9 months (p < 0.01). Following a main (time) effect [F(3, 32) = 
8.211, p < 0.01, multivariate partial eta squared = 0.44], post hoc comparisons 
observed significant differences existed between γ-tocopherol (μmol/L−1) base-
line and 9 month (p = 0.01), 4 and 9 month (p = 0.010) and between 6 to 9 
month (p < 0.01) values. See Table 4 for full antioxidant results. No significant 
interaction (time × group) effect, with no significant main (time) effect and no 
main (group) effect was observed for ascorbyl free radical (p > 0.05).  
3.4. Anthropometric Measurements  
Body mass (kg) showed no statistically significant interaction (group × time) ef-
fect with no significant main (time) effect or no significant main (group) effect 
(p > 0.05). Although non-significant, IG body mass (kg) displayed lowering trends 
from baseline to 4 months (96.24 ± 15.66 kg to 95.55 ± 15.6 kg) and from 4 
months to 6 months (95.55 ± 15.6 kg to 94.89 ± 16.36 kg). IG body mass dis-
played similar results from 6 months to follow-up (94.89 ± 16.36 kg to 95.00 ± 
16.50 kg; p > 0.05). In contrast, although non-significant (p > 0.05) UC body 
mass displayed an increasing trend from baseline to end of intervention (6 
months; 92.61 ± 18.53 kg to 93.23 ± 19.31 kg) (Table 1). No significant interac-
tion (group × time) effect with no main (time) effect or no significant main 
(group) effect were found for BMI (kg/m2; p > 0.05). Although non-significant 
IG BMI (kg/m2) values lowered from baseline to 9 months (34.19 ± 6.33 kg/m2, 
33.94 ± 6.05 kg/m2, 33.88 ± 6.65 kg/m2 to 33.80 ± 6.68 kg/m2 respectively) while 
UC BMI (kg/m2) increased marginally throughout the intervention (0 - 6 months; 
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32.72 ± 6.10 kg/m2 to 33.0 ± 5.70 kg/m2 respectively; p > 0.05). 
3.5. Dual-Energy X-Ray Absorptiometry (DXA)  
No significant interaction (time × group) effect, main (time) effect or main (group) 
effect was found in total body fat (%) (p > 0.05; IG total body fat (%) was 43.14 ± 
9.88 kg to 42.86 ± 9.98 kg (0 - 9 months respectively); UC total body fat (%) was 
43.27 ± 8.59 kg (baseline) and 43.45 ± 43.43 kg (9 months). No statistically sig-
nificant interaction (time × group) effect with no main (time) or main (group) 
effect was detected for regional fat (%), gynoid fat (%), total mass (kg), tissue 
mass (g), fat mass (g), lean mass (g), fat free mass (g) or z scores (p > 0.05). No 
statistically significant interaction (time × group) effect or main (time) effect was 
found for t-scores. A significant main (group) effect [F(1) = 7.766, p = 0.009] 
was found. The effect size found was large [partial eta squared = 0.186]. No sta-
tistically significant interaction (time × group) effect or main (group) effect was 
detected for BMC (g) (p > 0.05). A statistically significant main (time) effect was 
found between baseline and 6 month BMC (g) (IG 2829.50 ± 425.18 g to 2805 ± 
429.18 g; UC 2703.42 ± 518.32 g to 2692.53 ± 519.00 g) [F(2, 33.0)= 5.920, p = 
0.004]. The effect size was large [partial eta squared = 0.264]. IG android fat (%) 
displayed lowering trends during the intervention (0 - 6 months; 53.75% ± 
9.15% to 52.85% ± 8.69%) and at follow-up (to 52.69% ± 9.08%) although this 
was not significant (p > 0.05). UC android fat (%) displayed a similar pattern 
from baseline to 9 months (53.66% ± 8.24% to 53.66% ± 8.45% respectively; p > 
0.05). No statistically significant interaction (time × group) effect or no signifi-
cant main (group) effect was detected for A/G ratio (p > 0.05). Following a re-
peated measures GLM a significant main (time) effect was detected for A/G ratio 
[F(35) = 2, p = 0.011]. The effect size was large [partial eta squared = 0.240]. Post 
hoc analysis displayed a statistically significant difference between baseline and 6 
month A/G ratio scores (p = 0.08; IG 1.21 ± 0.24 and 1.18 ± 0.25 respectively; 
UC 1.18 ± 0.21 and 1.16 ± 0.21 respectively). 
3.6. Physical Fitness Assessment  
A significant interaction (time × group) effect was found for heart rate response 
at given speeds throughout the study [F(3, 32) = 3.073, p = 0.044, multivariate 
partial eta squared = 0.224]. Post hoc analysis found no significant difference 
between IG and UC at any assessment points (p > 0.05). Significant differences 
were found within UC for HR response at 4.2 km/hr−1 between 4 and 9 months 
(p = 0.34), for HR response to 5.2 km/hr−1 between 4 and 9 months (p = 0.016) 
and for HR response to 6.2 km/hr−1 between 6 and 9 months (p = 0.008) (Table 
5). No significant interaction (group × time) effect and no significant main 
(group) effect were observed for RPE. RPE displayed a significant main (time) 
effect. Post hoc comparisons found a statistical significance between baseline 
and 4 month (p = 0.024), baseline and 6 month (p < 0.001), baseline and 9 
month (p < 0.001) and 4 and 6 month RPE values (p = 0.013). Although no sig-
nificant interaction (time × group) effect was observed between groups (p >  
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Table 5. Physical fitness: sub-maximal treadmill walking assessment parameters. 
Parameter Assessment 
4.20 km/hr−1 5.20 km/hr−1 6.20 km/hr−1 
IG (n = 17) UC (n = 19) IG (n = 17) UC (n = 19) IG (n = 17) UC (n = 19) 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Heart rate 
(bpm−1) 
Baseline 100.68 14.15 99.75 11.68 112.03 17.05 111.07 13.97 125.90 22.45 127.20 19.61 
4 months 98.66 12.75 100.94¥ 8.49 111.86 16.24 112.63¥ 10.98 125.51 18.42 128.78 12.17 
6 months 97.11 14.09 100.35 8.19 108.81 17.38 113.09 10.41 126.04 20.35 131.16¥ 15.14 
9 months 100.30 15.95 96.21 9.26 112.90 18.50 108.07 12.25 127.70 18.29 124.77 14.09 
2OV  
(ml/kg/min−1) 
Baseline 10.18 2.64 10.75 2.75 11.91 2.62 12.48 3.03 14.15 2.57 15.01 4.00 
4 months 9.13 2.72 9.81 2.85 11.64 2.67 11.82 2.69 14.49 4.17 14.27 4.02 
6 months 9.69 2.51 11.07 1.73 12.43 2.61 13.10 2.05 15.59 2.20 15.69 2.40 
9 months 10.55 1.98 10.86 1.85 12.61 1.95 12.55 2.15 15.55 2.16 15.46 2.36 
2OV  
(L/min−1) 
Baseline 1.01 0.32 0.99 0.28 1.18 0.33 1.15 0.33 1.39 0.35 1.40 0.45 
4 months 0.92 0.32 0.92 0.32 1.13 0.36 1.09 0.34 1.40 0.49 1.32 0.49 
6 months 0.92 0.31 1.05 0.28 1.19 0.36 1.24 0.32 1.43 0.29 1.47 0.39 
9 months 1.01 0.28 0.99 0.27 1.23 0.32 1.18 0.30 1.48 0.38 1.44 0.36 
2COV  
(L/min−1) 
Baseline 0.78 0.26 0.80 0.24 0.97 0.26 0.99 0.29 1.19 0.31 1.25 0.42 
4 months 0.76 0.25 0.74 0.23 1.04 0.30 0.96 0.25 1.35 0.38 1.22 0.36 
6 months 0.75 0.26 0.85 0.25 1.04 0.34 1.08 0.31 1.22 0.40 1.36 0.41 
9 months 0.83 0.23 0.83 0.23 1.09 0.32 0.97 0.34 1.29 0.32 1.34 0.36 
METs 
Baseline 2.90 0.76 3.04 0.77 3.38 0.75 3.54 0.87 4.04 0.69 4.26 1.14 
4 months 2.58 0.78 2.78 0.79 3.29 0.73 3.34 0.74 4.09 1.10 4.04 1.14 
6 months 2.78 0.71 3.17 0.48 3.60 0.72 3.75 0.57 4.48 0.59 4.49 0.69 
9 months 3.06 0.56 3.04 0.59 3.68 0.54 3.60 0.62 4.50 0.62 4.41 0.68 
RPE 
Baseline 10.18 1.24 8.95 1.78 13.35 2.29 11.82 3.12 18.04 3.44 15.23 5.10 
4 months 9.32 2.14 8.30 2.22 12.63 2.20 11.14 3.40 16.55 3.89 14.42 5.06 
6 months 8.99 1.25 8.12 1.29 11.88 1.85 10.52 2.63 15.50 2.74 13.70 3.69 
9 months 8.97 1.96 8.67 1.48 11.69 2.23 10.76 3.09 15.00 2.76 13.82 4.80 
METs = metabolic equivalents, RPE = rate of perceived exertion. Repeated measures GLM examined differences between groups across assessment points 
(p < 0.05). ¥Denotes a within group significant difference between given value and 9 month value (p < 0.05). 
 
0.05), at 5.2 km/hr−1 and 6.2 km/hr−1 RPE displayed decreasing trends for both 
IG and UC across the study, IG RPE at 4.2 km/hr−1 decreased from baseline to 9 
months, while UC RPE at 4.2 km/hr−1 decreased from baseline to 6 months be-
fore displaying an increasing trend between 6 and 9 months (p > 0.05).  
3.7. Discussion 
To the author’s knowledge, this study is the first to demonstrate that walking to 
music with an individualized predetermined beat is a novel method to ensure PA 
guidelines for health can be achieved in a free-living environment for up to 9 
months. The results have shown that although walking compliance (volume and 
duration) decreased over the study period from 70(+39)% to 37.5(43.5)%; the 
majority of participants were able to attain their individualized moderate inten-
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sity target cadence between baseline to four months, four to six months and six 
to nine months (71.4%, 79.5% and 73.3% respectively). In other words, over 70% 
of the physical activity which they did complete was at least moderate intensity 
or higher. Achieving moderate intensity PA in those with IHG is of particular 
importance as it is well recognized to reduce the risk of glucometabolic and 
CVD complications [2]. Previous research by Tudor-Locke and Rowe [16] has 
indicated that regulating intensity of PA in a free-living environment remains 
problematic. As such these results in terms of attaining moderate PA in an 
“at-risk” population who should be targeted for PA behaviour change interven-
tions could be described as promising.  
3.7.1. Vascular Function and CVD Risk 
Despite these encouraging results in terms of attaining moderate intensity PA, 
one of themain findings of this study was that the current intervention was not 
effective in eliciting changes to the majority of glucometabolic and CVD bio-
markers assessed. Some significant improvements were found in vascular func-
tion; however these should be interpreted with care. SI, which reflects the mea-
surement of stiffness in the large arteries, displayed a significant main effect for 
time with values decreasing during the study (baseline to 6 months). RI values 
which reflect the vascular tone of the small arteries did not change throughout 
the study, however values positively decreased by 7.37% for the IG during the 
intervention in contrast to UC RI values which increased by 13.6% over the same 
period. FMD analysis demonstrated a significant interaction effect between 
groups at six months (IG, 6.51 ± 4.38 vs UC, 11.21 ± 5.72). Interestingly, signifi-
cant increases were observed within UC FMD (%) between 4 and 6 months 
(7.40 ± 2.85 and 11.21 ± 5.72 respectively). Whilst FMD in IG displayed a lo-
wering trend across all timepoints. Improvements in arterial stiffness and FMD 
are crucial in this population which are predisposed to increased CVD risk [26]. 
Research has highlighted the inverse relationship which exists between FMD and 
future cardiac event risk [27]. Indeed, a recent meta-analysis showed that for 
every 1% or 1 standard deviation decrease in FMD there is an associated in-
creased risk of 8% or 22% respectively of suffering a future CVD event [28]. Pre-
vious research has shown the reliability of FMD is a particularly intricate tech-
nique [29] and as such it is felt an important methodological concern which 
should be published in relation to the current population. FMD technique relies 
on skilled acquisition and interpretation of results [30] and as such requires rep-
lication in a larger cohort to confirm these findings. Several measurement issues 
are possible when assessing FMD in obese IHG populations, which require con-
sideration. These include sizing issues with cuff and plinth, inability to lie supine 
for required sampling and larger quantities of adipose tissue introducing diffi-
culty in isolating the brachial artery for analysis. Previous research has shown 
that improvements in SI and FMD may be the result of reduced circulating lipids 
and increased NO availability [26]. This study observed favorable improvements 
in FMD in the absence of improvements in lipoproteins, adipose tissue mass and 
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Hs-CRP (mg/L−1). Reductions in Hs-CRP are normally associated with increased 
nitric oxide (NO) expression which leads to enhanced NO bioavailability and 
improved FMD [31]. Although Hs-CRP did not change significantly, the ob-
served decreasing trends may have been sufficient to have impacted on FMD. 
However, it is important to consider the methodological issues encountered and 
note that statistical power of this study was based on two-hour glucose rather 
than FMD.  
3.7.2. Glycemic Control 
A main finding of this study was that the current intervention was not effective 
in significantly improving glycemic control (FPG and 2-hour glucose). IG 2-hour 
glucose decreased by 13.8% from baseline to 4 months while UC 2-hour glucose 
decreased by 3.8% during the same period. This is contrary to the PREPARE 
program by Yates and colleagues [32] who employed a structured educational 
process for IHG participants based on the DESMOND program [33] and did 
find significant differences in 2-hour glucose. It should be noted that previous 
studies which found significances in glucose metabolites were delivered by large 
multi-disciplinary teams beyond the scope of the current research [34] [35]. This 
again raises the question of whether behavioral support in the current study 
should have been extended and increased beyond the 6 month initial interven-
tion; however this has obvious time and fiscal implications. HbA1C identifies av-
erage plasma glucose over a period of approximately 8 to 12 weeks [24]. Al-
though no significance was found for HbA1C between groups, a significant main 
effect for time was displayed. Interestingly, although non-significant between 
groups at the end of the intervention (6 months) IG HbA1C displayed a 5.07% 
lower result in contrast to UC values. Furthermore, at follow-up (9 months) a 
4% difference was maintained (IG 36.81 ± 4.29 mmol/mol−1 vs. UC 38.28 ± 4.37 
mmol/mol−1). The UK prospective diabetes study group [36] has previously shown 
that reducing HbA1C by 11 mmol/mol−1 (or 1%) reduces the risk of individuals 
with T2DM developing diabetic associated complications. A 1% HbA1C reduc-
tion decreases the risk of mortality, myocardial infarction and microvascular 
complications by 14%, 21%, and 37% respectively [36]. Therefore, improving gly-
cemic control via a reduction in HbA1C is advantageous in IHG and has been 
achieved to some degree in this study.  
3.7.3. Anthropometry 
Previous IHG and T2DM interventions have focused on decreasing body mass 
in overweight individuals [34]. However, it is now clear that improved glucose 
metabolism and CVD risk reduction can be achieved in the absence of weight 
loss [37]. This study did not find a significant difference in body fat percentage. 
IG android fat (%) decreased from 53.8% ± 9.2% (baseline) to 52.9% ± 8.7% at 
the end of the intervention (6 months), decreases which were maintained at fol-
low up and within the UC group. Centrally located android (%) and gynoid (%) 
has been associated with increased risk of CVD [38] therefore these results sug-
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gest that IG android and gynoid fat (%) displayed favorable improvements.  
3.7.4. Inflammatory and Oxidative Stress Markers 
IL-6 and TNF-α are cytokines associated with skeletal muscle inflammation and 
feature in obesity related insulin sensitivity [39]. These increases cause the chroni-
cally stimulation of the NF-κB pathways which increases insulin resistance and 
β-cell dysfunction [40]. In turn, increased oxidative stress can be caused by ROS 
directly damaging cellular macromolecules [40]. In the current study a signifi-
cant main (time) effect was observed for IL-6 (pg/ml−1) from 6 to 9 months. 
While IL-6 (pg/ml−1) displayed a significant increase over time between 6 months 
and 9 months, it is worth noting follow-up concentrations remained lower for 
IG participants suggesting a reduced inflammatory response. Harris et al. [41] 
found that IL-6 (pg/ml−1) production during acute exercise is dependent on the 
intensity of activity and has the ability to directly inhibit TNF-α. In contrast to 
moderate (50% VO2max) and vigorous itensity (75% VO2max) activity (p < 0.05), 
one hour post low intensity activity (25% VO2max) elicited no significant effects 
on IL-6 (pg/ml−1) production [21]. In the current study no significance was ob-
served for TNF-α (pg/ml−1) however, IG TNF-α (pg/ml−1) displayed lowering 
trends from baseline to 4 months and recorded its lowest value at 9 months. In 
contrast UC TNF-α (pg/ml−1) values displayed non-significant increasing trends 
throughout the intervention and from baseline to follow-up (0 - 6 months and 0 
- 9 months). This may be due to the observed lack of reduction in fat mass pa-
rameters as has been found by Katsuki et al. [42]. Ascorbyl free radical and 
LOOHs are indicators of oxidative stress [43]. In the current study no statistical 
significance was found between groups for either of these markers. IG LOOHs 
increased from baseline to 9 months at each time point. Interestingly, a signifi-
cant interaction effect was observed for numerous lipid soluble antioxidants 
(γ-tocopherol and α-tocopherol, retinol and lycopene. IG γ-tocopherol and α-to- 
copherol displayed similar patterns, increasing continually from baseline to fol-
low-up. In contrast UC values decreased throughout the intervention (0 - 6 
months). Similarly, IG retinol increased from baseline to 9 months (43.61%) 
across all assessment points while UC retinol decreased throughout the study. IG 
lycopene displayed favorable increases from baseline to 6 months and in contrast 
UC lycopene decreased throughout the study. It may be suggested that the in-
creased antioxidant defense observed above may have been sufficient to control 
any oxidative stress caused by increased moderate intensity activity. Dietary ma-
nipulation did not form part of the study but it is possible that the increase in PA 
led to changes in antioxidant intake as observed in previous research [44]. 
4. Conclusion  
To the authors’ knowledge, this is the first study to demonstrate that using mu-
sic with a predetermined tempo can assist overweight adults with IHG to regu-
late their walking cadence to moderate intensity in a free-living environment. 
Furthermore, we have demonstrated that it is feasible to complete a 6 month 
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walking to music intervention in an “at risk” population assessing a comprehen-
sive range of physiological measures and biomarkers at 4 time points (including 
9 month follow up). This study showed the novel walking intervention and indi-
vidualized PACs were not more effective than standard NHS care in managing 
glucose metabolism overweight adults with IHG. This study did achieve signifi-
cant improvements in FMD (mainly in the UC group); however, as discussed 
previously, these findings should be accepted with caution. A number of signifi-
cant metabolic health improvements were observed over time but not between 
groups. It is suggested that future research examines the effect of walking to mu-
sic with these parameters as primary outcome measures. It is strongly recom-
mended that behavior change support embedded within PA interventions should 
be maintained for as long as feasibly and financially possible to determine whether 
effects on similar parameters may be improved. 
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